Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Autor: Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands. Electronic address: a.j.gelderblom@lumc.nl., Bhadri V; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia., Stacchiotti S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bauer S; Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany., Wagner AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., van de Sande M; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Bernthal NM; Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, CA, USA., López Pousa A; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Razak AA; Princess Margaret Cancer Center, Toronto, ON, Canada., Italiano A; Department of Medical Oncology, Institut Bergonié, Bordeaux, France; University of Bordeaux, Bordeaux, France., Ahmed M; University College London Hospitals NHS Foundation Trust, London, UK., Le Cesne A; Department of Cancer Medicine, Gustave Roussy, Villejuif, France., Tinoco G; Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH, USA., Boye K; Department of Oncology, Oslo University Hospital, Oslo, Norway., Martín-Broto J; Fundación Jiménez Díaz University Hospital, University Hospital General de Villalba, Instituto de Investigactión Sanitaria Fundación Jiménez Díaz, Madrid, Spain., Palmerini E; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Tafuto S; Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Naples, Italy., Pratap S; Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Powers BC; Department of Internal Medicine, Medical Oncology Division, University of Kansas Cancer Center, Overland Park, KS, USA., Reichardt P; Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Casado Herráez A; Department of Medical Oncology, Hospital Universitario San Carlos, Madrid, Spain., Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Tait C; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Zarins F; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Harrow B; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Sharma MG; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Ruiz-Soto R; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Sherman ML; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Blay JY; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Tap WD; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.

Publikováno v: Lancet (London, England) [Lancet] 2024 Jun 22; Vol. 403 (10445), pp. 2709-2719. Date of Electronic Publication: 2024 Jun 03.

SA78 The Burden of Surgery for Tenosynovial Giant Cell Tumor: A Targeted Review.

Autor: Harrow, B.¹ (AUTHOR), Lee, M.D.² (AUTHOR), Kaiser, E.² (AUTHOR), Zeringo, N.³ (AUTHOR)

Publikováno v: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS629-S630. 2p.

1770P Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

Autor: D'Amato, G., Wagner, A.J., Ganjoo, K.N., Stacchiotti, S., Gelderblom, H., Ryan, C.W., Palmerini, E., Ravi, V., Saleh, R., Le Cesne, A., Bernthal, N.M., van de Sande, M., Narasimhan, S., Harrow, B., Saunders, A., Ruiz-Soto, R., Sherman, M.L., Tap, W.D.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S1054-S1054

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.

Autor: Gelderblom H; Leiden University Medical Center, Leiden, the Netherlands., Jones RL; Royal Marsden Hospital and Institute of Cancer Research, London, UK., Blay JY; Centre Léon Bérard and University Claude Bernard Lyon 1, Lyon, France., George S; Dana-Farber Cancer Institute, Boston, MA, USA., von Mehren M; Fox Chase Cancer Center, Philadelphia, PA, USA., Zalcberg JR; Department of Medical Oncology, Alfred Health and School of Public Health, Monash University, Melbourne, Australia., Kang YK; Asan Medical Center, University of Ulsan, Seoul, Korea., Razak AA; Princess Margaret Cancer Centre, Toronto, ON, Canada., Trent J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Attia S; Mayo Clinic, Jacksonville, FL, USA., Le Cesne A; Gustave Roussy, Vellejuif, France., Siontis BL; Mayo Clinic, Rochester, MN, USA., Goldstein D; Prince of Wales Hospital and Clinical School University of New South Wales, New South Wales, Australia., Boye K; Department of Oncology, Oslo University Hospital, Oslo, Norway., Sanchez C; Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Steeghs N; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland., Druta M; Moffit Cancer Center, Tampa, FL, USA., Serrano C; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Somaiah N; MD Anderson Cancer Center, Houston, TX, USA., Chi P; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Harrow B; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA. Electronic address: brooke.harrow@deciphera.com., Becker C; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Reichmann W; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Sherman ML; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Ruiz-Soto R; Deciphera Pharmaceuticals, LLC, Waltham, MA, USA., Heinrich MC; Portland VA Healthcare System and Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA., Bauer S; Department of Medical Oncology and Sarcoma Center at the West German Cancer Center, University Hospital Essen, Essen, Germany; German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Oct; Vol. 192, pp. 113245. Date of Electronic Publication: 2023 Jul 20.

An Introduction to Organic Chemistry. Fifth edition (Lowy, A.; Harrow, B.)

Autor: Ralph E. Dunbar

Publikováno v: Journal of Chemical Education. 18:99

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42ee7e26ad44f417739a7fb486239891
https://doi.org/10.1021/ed018p99.4